12:00 AM
Feb 11, 2013
 |  BC Week In Review  |  Company News  |  Other News

Novo Nordisk endocrine/metabolic news

The company said the facility can produce its insulins as well as diabetes drug Victoza liraglutide, but noted that there are several filling plants available to produce its products. Novo Nordisk, which submitted its response on Dec....

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >